Get started
Author

Chengquan Shen

Observed names: C. Shen, Shen, Chengquan
ORCID: 0000-0001-8402-2271
Observed ORCID: 0000-0001-8402-2271
OpenAlex ID: A5018095992
Identification and verification of an immune-related lncRNA signature for predicting the prognosis of patients with bladder cancer
2020 · Jirong Wang, Chengquan Shen, et al. · International Immunopharmacology · 63
Development and validation of a prognostic immune-associated gene signature in clear cell renal cell carcinoma
2020 · Chengquan Shen, Jing Liu, et al. · International Immunopharmacology · 53
A feed-forward loop based on aerobic glycolysis and TGF-β between tumor-associated macrophages and bladder cancer cells promoted malignant progression and immune escape
2023 · Chengquan Shen, Jing Liu, et al. · Journal of Cancer Research and Clinical Oncology · 28
PDF
NOTCH3 promotes malignant progression of bladder cancer by directly regulating SPP1 and activating PI3K/AKT pathway
2024 · Changxue Liu, Huaixi Ge, et al. · Cell Death and Disease · 27
PDF
N6-Methyladenosine enhances the translation of ENO1 to promote the progression of bladder cancer by inhibiting PCNA ubiquitination
2024 · Chengquan Shen, Jing Liu, et al. · Cancer Letters · 26
High expression of COL6A1 predicts poor prognosis and response to immunotherapy in bladder cancer
2022 · Xuezhou Zhang, Jing Liu, et al. · Cell Cycle · 25
The Analysis of PTPN6 for Bladder Cancer: An Exploratory Study Based on TCGA
2020 · Chengquan Shen, Jing Liu, et al. · Disease Markers · 18
PDF
Identification of metabolism-associated genes and construction of a prognostic signature in bladder cancer
2020 · Chengquan Shen, Jing Liu, et al. · Cancer Cell International · 15
PDF
Tumor-intrinsic ENO1 inhibition promotes antitumor immune response and facilitates the efficacy of anti-PD-L1 immunotherapy in bladder cancer
2025 · Chengquan Shen, Jing Liu, et al. · Journal of Experimental & Clinical Cancer Research · 14
Ferroptosis Biomarkers for Predicting Prognosis and Immunotherapy Efficacy in Adrenocortical Carcinoma
2022 · Chengquan Shen, Yonghua Wang · Archives of Medical Research · 12
TEAD4 is an Immune Regulating-Related Prognostic Biomarker for Bladder Cancer and Possesses Generalization Value in Pan-Cancer
2021 · Jirong Wang, Chengquan Shen, et al. · DNA and Cell Biology · 12
The effectiveness and safety of RC48 alone or in combination with PD-1 inhibitors for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study
2025 · Huaixi Ge, Changxue Liu, et al. · Journal of Translational Medicine · 11
High expression of GMNN predicts malignant progression and poor prognosis in ACC
2022 · Xinzhao Zhao, Xuezhou Zhang, et al. · European journal of medical research · 11
PDF
Development and Validation of an m6A RNA Methylation Regulators-Based Signature for Predicting the Prognosis of Adrenocortical Carcinoma
2021 · Chengquan Shen, Jing Liu, et al. · Frontiers in Endocrinology · 10
PDF
Construction of an Immune-Associated Gene-Based Signature in Muscle-Invasive Bladder Cancer
2020 · Chengquan Shen, Ting Xu, et al. · Disease Markers · 9
PDF
Identification and validation of a signature based on myofibroblastic cancer-associated fibroblast marker genes for predicting prognosis, immune infiltration, and therapeutic response in bladder cancer
2024 · Ruize Qin, Xiaocheng Ma, et al. · Korean journal of urology · 5
Targeting RRBP1 reverses immune evasion and enhances immunotherapy efficacy via the CXCL10-CXCR3 axis in bladder cancer
2026 · Chengquan Shen, Changxue Liu, et al. · Journal for ImmunoTherapy of Cancer · 4
Construction of a immune-associated genes based prognostic signature in bladder cancer
2021 · Chengquan Shen, Liping Wang, et al. · Artificial Cells Nanomedicine and Biotechnology · 4
Integrating machine learning and structural analysis to decipher benzo[a]pyrene-induced bladder cancer networks
2026 · Xinzhao Zhao, Ruize Qin, et al. · Discover Oncology · 1
PIK3CA Mutation Is an Adverse Prognostic Factor in HPV-Associated Oropharynx Cancer
2019 · B. Beaty, G.P. Gupta, et al. · International Journal of Radiation Oncology*Biology*Physics · 1
PDF
Integrating network pharmacology and molecular simulations to identify Doconexent-associated regulatory networks in renal cell carcinoma
2026 · Xinzhao Zhao, Ruize Qin, et al. · BMC Urology
NOTCH3 regulates myofibroblastic CAF differentiation via the P62–ROS signaling axis to promote bladder cancer progression
2026 · Ding Hu, Chengquan Shen, et al. · Journal of Experimental & Clinical Cancer Research
NOTCH3 regulates myofibroblastic CAF differentiation via the P62–ROS signaling axis to promote bladder cancer progression
2026 · Ding Hu, Chengquan Shen, et al. · Figshare
Additional file 1 of NOTCH3 regulates myofibroblastic CAF differentiation via the P62–ROS signaling axis to promote bladder cancer progression
2026 · Ding Hu, Chengquan Shen, et al. · Figshare
Combining machine learning and molecular docking to unravel the molecular network of bladder cancer induced by 2-naphthylamine
2025 · Ruize Qin, Cheng Li, et al. · Discover Oncology
Works count: 41
Citation count: 349
H-index: 11
I10-index: 14
Year
Topic
Type